| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.13 | 0.1 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.06 | 0.1 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | -0.075 | 0.1 |
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | -0.083 | 0.1 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | 0.071 | 0.1 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.081 | 0.1 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.1 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |